XML 116 R64.htm IDEA: XBRL DOCUMENT v2.4.1.9
BUSINESS COMBINATIONS - Pro forma impact of business combinations (Details) (USD $)
In Millions, except Per Share data, unless otherwise specified
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Pro forma of consolidated results of operations      
Revenues $ 8,348.9us-gaap_BusinessAcquisitionsProFormaRevenue $ 7,929.9us-gaap_BusinessAcquisitionsProFormaRevenue $ 7,700.6us-gaap_BusinessAcquisitionsProFormaRevenue
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc. $ 909.3us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss $ (801.9)us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss $ (709.6)us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:      
Basic (in usd per share) $ 2.71us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic $ (2.43)us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic $ (2.14)us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic
Diluted (in usd per share) $ 2.66us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted $ (2.43)us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted $ (2.14)us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted